Henry Schein (HSIC) investor relations material

Business performance and growth

• Strong Q1 with healthy growth in dental, technology, and distribution; medical showed mid-single digit growth when excluding flu-related products.

• Margins expanded, and value creation targets of $125M run rate by year-end and $200M over the next few years reaffirmed.

• Guidance for 2026 reconfirmed, with ongoing focus on operational improvements and productivity.

• Dental business momentum continued into Q2, with market share gains and strong customer retention.

• Medical business, excluding diagnostic kits, grew mid-single digits; home solutions now over 10% of medical revenue and growing faster than core.

Strategic priorities and initiatives

• CEO’s first 100 days focused on learning from customers, suppliers, and employees, and assessing current projects.

• Key priorities include leveraging AI for product development and aligning commercial processes to enhance customer value propositions.

• Value creation initiatives span dynamic pricing, own brands, specialty growth, and centralizing back office functions, with a continuous improvement mindset.

• Gross profit optimization and G&A restructuring expected to deliver back-loaded benefits in 2026, with immediate gains from pricing initiatives.

Market and customer insights

• DSOs remain a major growth driver, with opportunities to expand corporate brand adoption and technology solutions over multiple years.

• Promotional activities in 2025 led to market share gains and improved customer relationships in 2026.

• Specialty segment grew 8%, with value implants outpacing premium; recent acquisitions like S.I.N. U.S. distributor expected to drive further growth.

• Digital equipment volumes are rising, but lower ASPs from new entrants are impacting revenue; adoption of digital tech seen as a long-term growth lever.